FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2087681115> ?p ?o ?g. }

• W2087681115 endingPage "907" @default.
• W2087681115 startingPage "899" @default.
• W2087681115 abstract "The resounding success of combination antiretroviral efficacy for both treatment-naïve and treatment-experienced patients – with 70–90% viral suppression rates in recent studies – has made registration trials for new agents challenging. With the inevitable specter of drug resistance, new agents must have a pathway to approval. The Forum for Collaborative HIV Research obtained input from concerned stakeholders including industry, clinical sciences, community advocacy, and regulatory sciences (Food and Drug Administration and European Medicines Agency) to discuss how safety and efficacy of new agents could be demonstrated. Recognizing the shortfalls of superiority or noninferiority trials in this environment, a new trial design for treatment-experienced patients, minimizing the risk for drug resistance but allowing full assessment of safety, was proposed. The antiviral efficacy of an active investigational drug would be assessed by comparison to placebo as an add-on to a failing regimen in a short, 10–14-day study followed by institution of an optimized background regimen (OBR) in both arms with investigational drug given to all patients. The follow-on stage would assess dose response, safety, durability of initial response, and development of resistance. Additionally, a second safety trial could be conducted comparing patients randomized to the investigational agent with a new OBR to those on a new OBR and placebo. Finally, approval decisions could consider other long-term safety endpoints. Exposing treatment-naïve patients to investigational agents remains a controversial issue; stakeholders have different interpretations of risk–benefit for trials in this population that necessitate careful consideration before initiating trials in them." @default.
• W2087681115 created "2016-06-24" @default.
• W2087681115 creator A5028775745 @default.
• W2087681115 creator A5045543422 @default.
• W2087681115 creator A5046146816 @default.
• W2087681115 creator A5055039896 @default.
• W2087681115 creator A5062018854 @default.
• W2087681115 creator A5065417571 @default.
• W2087681115 creator A5075443101 @default.
• W2087681115 creator A5084329965 @default.
• W2087681115 date "2012-05-15" @default.
• W2087681115 modified "2023-10-15" @default.
• W2087681115 title "Novel clinical trial designs for the development of new antiretroviral agents" @default.
• W2087681115 cites W1497170016 @default.
• W2087681115 cites W1983837630 @default.
• W2087681115 cites W1985722970 @default.
• W2087681115 cites W1987680111 @default.
• W2087681115 cites W1988062692 @default.
• W2087681115 cites W1996313031 @default.
• W2087681115 cites W1997304902 @default.
• W2087681115 cites W2007535230 @default.
• W2087681115 cites W2030627771 @default.
• W2087681115 cites W2048897812 @default.
• W2087681115 cites W2049969210 @default.
• W2087681115 cites W2076339980 @default.
• W2087681115 cites W2103513664 @default.
• W2087681115 cites W2110442882 @default.
• W2087681115 cites W2110937893 @default.
• W2087681115 cites W2118571087 @default.
• W2087681115 cites W2119433625 @default.
• W2087681115 cites W2121179908 @default.
• W2087681115 cites W2135594909 @default.
• W2087681115 cites W2139772076 @default.
• W2087681115 cites W2139998551 @default.
• W2087681115 cites W2142538462 @default.
• W2087681115 cites W2150504993 @default.
• W2087681115 cites W2156933277 @default.
• W2087681115 cites W2158934554 @default.
• W2087681115 cites W2160599390 @default.
• W2087681115 cites W4241267536 @default.
• W2087681115 doi "https://doi.org/10.1097/qad.0b013e3283519371" @default.
• W2087681115 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3343181" @default.
• W2087681115 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22954760" @default.
• W2087681115 hasPublicationYear "2012" @default.
• W2087681115 type Work @default.
• W2087681115 sameAs 2087681115 @default.
• W2087681115 citedByCount "12" @default.
• W2087681115 countsByYear W20876811152012 @default.
• W2087681115 countsByYear W20876811152013 @default.
• W2087681115 countsByYear W20876811152014 @default.
• W2087681115 countsByYear W20876811152015 @default.
• W2087681115 countsByYear W20876811152017 @default.
• W2087681115 countsByYear W20876811152020 @default.
• W2087681115 countsByYear W20876811152021 @default.
• W2087681115 countsByYear W20876811152022 @default.
• W2087681115 crossrefType "journal-article" @default.
• W2087681115 hasAuthorship W2087681115A5028775745 @default.
• W2087681115 hasAuthorship W2087681115A5045543422 @default.
• W2087681115 hasAuthorship W2087681115A5046146816 @default.
• W2087681115 hasAuthorship W2087681115A5055039896 @default.
• W2087681115 hasAuthorship W2087681115A5062018854 @default.
• W2087681115 hasAuthorship W2087681115A5065417571 @default.
• W2087681115 hasAuthorship W2087681115A5075443101 @default.
• W2087681115 hasAuthorship W2087681115A5084329965 @default.
• W2087681115 hasBestOaLocation W20876811151 @default.
• W2087681115 hasConcept C126322002 @default.
• W2087681115 hasConcept C141071460 @default.
• W2087681115 hasConcept C141341695 @default.
• W2087681115 hasConcept C142724271 @default.
• W2087681115 hasConcept C148482608 @default.
• W2087681115 hasConcept C177713679 @default.
• W2087681115 hasConcept C204787440 @default.
• W2087681115 hasConcept C27081682 @default.
• W2087681115 hasConcept C2780035454 @default.
• W2087681115 hasConcept C2781413609 @default.
• W2087681115 hasConcept C2908647359 @default.
• W2087681115 hasConcept C502991105 @default.
• W2087681115 hasConcept C535046627 @default.
• W2087681115 hasConcept C64903051 @default.
• W2087681115 hasConcept C71924100 @default.
• W2087681115 hasConcept C98274493 @default.
• W2087681115 hasConcept C99454951 @default.
• W2087681115 hasConceptScore W2087681115C126322002 @default.
• W2087681115 hasConceptScore W2087681115C141071460 @default.
• W2087681115 hasConceptScore W2087681115C141341695 @default.
• W2087681115 hasConceptScore W2087681115C142724271 @default.
• W2087681115 hasConceptScore W2087681115C148482608 @default.
• W2087681115 hasConceptScore W2087681115C177713679 @default.
• W2087681115 hasConceptScore W2087681115C204787440 @default.
• W2087681115 hasConceptScore W2087681115C27081682 @default.
• W2087681115 hasConceptScore W2087681115C2780035454 @default.
• W2087681115 hasConceptScore W2087681115C2781413609 @default.
• W2087681115 hasConceptScore W2087681115C2908647359 @default.
• W2087681115 hasConceptScore W2087681115C502991105 @default.
• W2087681115 hasConceptScore W2087681115C535046627 @default.
• W2087681115 hasConceptScore W2087681115C64903051 @default.
• W2087681115 hasConceptScore W2087681115C71924100 @default.
• W2087681115 hasConceptScore W2087681115C98274493 @default.

• next